Eisai Creates US Subsidiary H3 Biomedicine with up to $200M

H3 Biomedicine will use a pharmacogenomic approach to develop new oncology drugs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.